Table 3. Grade 3 and 4 toxicity (adverse events considered at least possibly related to everolimus) was observed in 68% (52/77) of patients.
| Toxicity | Grade | Total (%) | |
|---|---|---|---|
| 3 | 4 | ||
| General | |||
| Fatigue | 6 | 0 | 6 (8) |
| Mouth sores (mucositis) | 2 | 0 | 2 (3) |
| Anorexia | 1 | 0 | 1 (1) |
| Fever | 1 | 0 | 1 (1) |
| Dehydration | 1 | 0 | 1 (1) |
| Hypersensitivity | 0 | 1 | 1 (1) |
| Edema | 1 | 0 | 1 (1) |
| Hematologic | |||
| Anemia | 10 | 1 | 11 (14) |
| Neutropenia | 12 | 2 | 14 (18) |
| Thrombocytopenia | 17 | 12 | 29 (38) |
| Metabolic | |||
| Hyperglycemia | 6 | 0 | 6 (8) |
| Hypertriglyceridemia | 1 | 1 | 2 (3) |
| Hypercholesterolemia | 1 | 0 | 1 (1) |
| Hyponatremia | 1 | 0 | 1 (1) |
| Hypokalemia | 0 | 1 | 1 (1) |
| Tumor lysis syndrome | 1 | 0 | 1 (1) |
| Renal failure | 0 | 1 | 1 (1) |
| Hepatic | |||
| Aspartate aminotransferase | 1 | 0 | 1 (1) |
| Infection | |||
| Respiratory | 3 | 0 | 3 (4) |
| Skin | 2 | 0 | 2 (3) |
| Urinary tract | 1 | 0 | 1 (1) |
| Perianal | 1 | 0 | 1 (1) |
| Pulmonary | |||
| Cough | 1 | 0 | 1 (1) |
| Hypoxia | 1 | 0 | 1 (1) |
| Dyspnea | 1 | 0 | 1 (1) |
| Pneumonitis | 1 | 0 | 1 (1) |
A total of 34 patients (44%) experienced at least one grade 3 toxicity and 18 (23%) experienced at least one grade 4 toxicity.